Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;38(4):493-508.
doi: 10.1007/s10719-020-09937-9. Epub 2020 Aug 13.

Comparison of polysaccharide glycoconjugates as candidate vaccines to combat Clostridiodes (Clostridium) difficile

A D Cox  1 , F St Michael  2 , A Aubry  2 , P C R Strong  2 , A C Hayes  2 , S M Logan  2
Affiliations

Comparison of polysaccharide glycoconjugates as candidate vaccines to combat Clostridiodes (Clostridium) difficile

A D Cox et al. Glycoconj J. 2021 Aug.

Abstract

Two known Clostridiodes (Clostridium) difficile surface antigens, a lipoteichoic acid (LTA) and a polysaccharide (PS-II) were isolated and purified in order to prepare glycoconjugate vaccines to the carrier protein human serum albumin utilising a reductive amination strategy. Mice and rabbits were immunized with a prime and two boost strategy and the resulting sera were examined for their ability to recognise the purified homologous antigens and subsequently killed whole cells of C. difficile strains and other Clostridia species. Immunisation derived antisera from rabbits and mice, recognised all strains of C. difficile vegetative cells examined, with generally similar titers from animals that received the LTA or the PS-II conjugates. Sera raised to the LTA conjugates were able to recognise other Clostridia species C. butyricum, C. bifermentans and C. subterminale whereas sera raised to the PS-II conjugates were not. These LTA and PS-II sera recognised live cells in an immunofluorescence assay and were also able to recognise the spore form of the bacterium. This study has confirmed that the LTA and PS-II polysaccharides are both highly conserved surface polymers of C. difficile that are easily accessible to the immune system and as such may have potential as vaccine antigens or as targets for therapeutics to combat C. difficile infection.

Keywords: Capsular polysaccharide PS-II; Clostridiodes difficile; Conjugate vaccine; Lipoteichoic acid.

PubMed Disclaimer

References

    1. Shah, D., Dang, M.-D., Hasbun, R., Koo, H.L., Jiang, Z.-D., DuPont, H.L., Garey, K.W.: Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Exp. Rev. Anti-Infect. Ther. 8, 555–564 (2010) - DOI
    1. Mascio, C.T.M., Mortin, L.I., Howland, K.T., van Praagh, A.D.G., Zhang, S., Arya, A., Chuong, C.L., Kang, C., Li, T., Silverman, J.A.: In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob. Ag. Chemother. 56, 5023–5030 (2012) - DOI
    1. Spigaglia, P.: Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther. Adv. Inf. Dis. 3, 23–42 (2016)
    1. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G., Thomas Jr., W.D., Leney, M., Sloan, S., Hay, C.A., Ambrosino, D.M.: Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl. J. Med. 362, 197–205 (2010) - DOI
    1. Hussack, G., Arbabi-Ghahroudi, M., van Faassen, H., Songer, J.G., Ng, K.K.-S., MacKenzie, R., Tanha, J.: Neutralization of Clostridium difficile toxin a with single-domain antibodies targeting the cell receptor binding domain. J. Biol. Chem. 286, 8961–8976 (2011) - DOI

LinkOut - more resources